Dodge & Cox Has $1.06 Billion Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY

Dodge & Cox lessened its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 27.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,321,230 shares of the biopharmaceutical company’s stock after selling 875,866 shares during the quarter. Dodge & Cox owned about 1.76% of Alnylam Pharmaceuticals worth $1,058,481,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in ALNY. Root Financial Partners LLC acquired a new position in Alnylam Pharmaceuticals during the 3rd quarter worth approximately $25,000. Salomon & Ludwin LLC acquired a new stake in Alnylam Pharmaceuticals in the third quarter valued at approximately $27,000. Ameriflex Group Inc. bought a new stake in shares of Alnylam Pharmaceuticals during the third quarter valued at approximately $32,000. ORG Partners LLC increased its holdings in shares of Alnylam Pharmaceuticals by 70.2% during the third quarter. ORG Partners LLC now owns 80 shares of the biopharmaceutical company’s stock valued at $36,000 after acquiring an additional 33 shares in the last quarter. Finally, Aster Capital Management DIFC Ltd bought a new stake in shares of Alnylam Pharmaceuticals during the third quarter valued at approximately $36,000. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY opened at $313.41 on Friday. The stock has a 50 day moving average of $344.35 and a 200 day moving average of $410.04. The company has a market capitalization of $41.56 billion, a price-to-earnings ratio of 183.28 and a beta of 0.36. Alnylam Pharmaceuticals, Inc. has a 12 month low of $205.87 and a 12 month high of $495.55. The company has a current ratio of 2.76, a quick ratio of 2.71 and a debt-to-equity ratio of 1.28.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share for the quarter, missing the consensus estimate of $1.43 by ($0.18). Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The business had revenue of $1.10 billion during the quarter, compared to analysts’ expectations of $1.16 billion. During the same period in the prior year, the firm posted ($0.65) EPS. The firm’s revenue for the quarter was up 84.9% on a year-over-year basis. As a group, sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. Wells Fargo & Company cut their target price on Alnylam Pharmaceuticals from $479.00 to $376.00 and set an “equal weight” rating on the stock in a report on Tuesday, January 20th. Oppenheimer started coverage on shares of Alnylam Pharmaceuticals in a research note on Wednesday, January 7th. They set an “outperform” rating and a $500.00 price target for the company. Freedom Capital upgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Tuesday, February 17th. HC Wainwright reaffirmed a “buy” rating and issued a $510.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Wednesday, February 18th. Finally, Morgan Stanley decreased their target price on shares of Alnylam Pharmaceuticals from $495.00 to $408.00 and set an “equal weight” rating for the company in a research report on Friday, January 30th. One analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $477.96.

Insider Activity at Alnylam Pharmaceuticals

In related news, EVP Pushkal Garg sold 2,242 shares of the stock in a transaction dated Friday, February 13th. The shares were sold at an average price of $310.08, for a total transaction of $695,199.36. Following the completion of the transaction, the executive vice president owned 24,848 shares in the company, valued at approximately $7,704,867.84. This represents a 8.28% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Kevin Joseph Fitzgerald sold 2,290 shares of the firm’s stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $370.33, for a total transaction of $848,055.70. Following the sale, the executive vice president owned 21,264 shares of the company’s stock, valued at $7,874,697.12. This trade represents a 9.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 53,923 shares of company stock valued at $18,072,087 over the last quarter. Corporate insiders own 1.50% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.